Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:SCNX

Scienture Q1 2025 Earnings Results & Report

Scienture logo
$3.91 +0.15 (+3.99%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$3.96 +0.05 (+1.28%)
As of 10/12/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture reported Q1 2025 earnings on May 12, 2025. The company reported EPS of -$8.25, while revenue was $0.01 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

Scienture EPS Results

Actual EPS
-$8.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Scienture Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Scienture's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Scienture's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Scienture Q1 2025 Earnings FAQ

Scienture (NASDAQ:SCNX) reported earnings of -$8.25 per share for Q1 2025. The report was announced on Monday, May 12, 2025.

Scienture reported revenue of $0.01 million for Q1 2025.

Scienture's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scienture on the company's earnings history page.

Scienture Earnings Headlines

Contrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095564
SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 5, 2026  |  marketscreener.comM
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
 |  Stansberry Research (Ad)
What is Maxim Group's Estimate for Scienture Q3 Earnings?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085394
Exclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptions
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/exclusive-scienture-expands-institutional-reach-for-hypertension-drug-with-new-hospital-adoptions/ar-AA2dpL8b
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373784/0/en/scienture-announces-arbli-added-to-formularies-at-three-leading-u-s-pediatric-academic-medical-centers-and-hospitals.html
See More Scienture Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email.

About Scienture

Scienture (NASDAQ:SCNX) is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its areas of interest include neurological and psychiatric conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain.

The company’s portfolio includes prescription pharmaceutical products and product candidates intended to provide alternative delivery methods or other potential benefits compared with existing treatments. Scienture has identified ZolpiMist, an FDA-approved oral spray formulation of zolpidem tartrate for the short-term treatment of insomnia, as part of its commercial and development portfolio.

Scienture primarily serves the U.S. pharmaceutical market and is focused on advancing, obtaining regulatory approval for, and commercializing therapies in its targeted CNS categories. The company’s operations and product strategy may evolve as it develops its pipeline and pursues commercialization opportunities.

View Scienture Profile
Earnings Tools